Photo from wikipedia
Although patients with EGFR‐mutant non‐small‐cell lung cancer (NSCLC) benefit from treatment with EGFR‐tyrosine kinase inhibitors (TKIs), outcomes are limited by the eventual development of acquired resistance. We conducted a retrospective… Click to show full abstract
Although patients with EGFR‐mutant non‐small‐cell lung cancer (NSCLC) benefit from treatment with EGFR‐tyrosine kinase inhibitors (TKIs), outcomes are limited by the eventual development of acquired resistance. We conducted a retrospective study to evaluate the efficacy and feasibility of EGFR‐TKI therapy beyond focal progression, associated with microwave ablation.
Keywords:
cell lung;
egfr tyrosine;
non small;
small cell;
tyrosine kinase
Journal Title: Thoracic Cancer
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Thoracic Cancer
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!